Nucleus Remodeling, Inc.
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Nucleus Remodeling, Inc. (“The Company”), is a biotech start-up focused on developing therapeutic cells for use in regenerative medicine. The Company has clear title to patent applications directed to novel methods of making multiple different cell types from a patient’s own skin cells.
The Company is seeking investments to further develop the technology that will lead to cell therapies.
Economically valuable areas of cell therapy include diabetes, cardiomyopathy, Parkinson’s disease, and/or osteoarthritis.
Since the cells for these therapies are derived from the patient’s own tissue, there is no question of cell rejection. There are no moral issues.
For its first project, the Company already has plans to further develop in vitro insulin-producing cells to treat diabetes. This project in itself is staggering in its economic value. The Company intends to develop the insulin-producing cells through the pre-clinical stage, then partner with a large biotechnology or pharmaceutical company for clinical trials and beyond.
It will take 3-5 years to demonstrate the efficacy of our products in animal models. We can then liquidate the first round of investments through upfront licensing payments, a second round of financing, or via merger or acquisition.|